Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 11,790,000 shares, a decrease of 5.1% from the October 15th total of 12,420,000 shares. Based on an average daily volume of 1,120,000 shares, the days-to-cover ratio is presently 10.5 days.

Institutional Investors Weigh In On Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of CTXR. Point72 DIFC Ltd acquired a new position in Citius Pharmaceuticals during the second quarter valued at $29,000. BNP Paribas Financial Markets raised its stake in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after buying an additional 32,686 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Citius Pharmaceuticals during the 3rd quarter valued at about $47,000. Miller Investment Management LP lifted its holdings in shares of Citius Pharmaceuticals by 99.3% in the 3rd quarter. Miller Investment Management LP now owns 99,640 shares of the company’s stock valued at $50,000 after buying an additional 49,640 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Citius Pharmaceuticals in the second quarter worth about $69,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th.

Citius Pharmaceuticals Stock Performance

Citius Pharmaceuticals stock opened at $0.22 on Tuesday. The business’s 50-day simple moving average is $0.43 and its two-hundred day simple moving average is $0.60. The company has a market cap of $40.52 million, a PE ratio of -0.93 and a beta of 1.66. Citius Pharmaceuticals has a fifty-two week low of $0.19 and a fifty-two week high of $1.07.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.